Phase 3 Uveitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You (or your child) agreed to take part and gave signed consent or assent to join the study
- You must have completed 52 weeks of treatment in the main (core) study and be under 18 years old at the time of signing the consent form
- Your BMI (a measure of body weight relative to height) must be at or above the 5th percentile for your age and sex, based on CDC growth charts
- You are willing and able to attend all scheduled study visits and follow the study's requirements
- Your doctor has determined that continuing treatment with the study drug (apremilast) is considered safe and beneficial for you
Who may not be able to join:
- Anyone who answered "yes" to any question on a suicide-related questionnaire (called the C-SSRS) at their Week 52 visit in the main study
- Anyone who has a surgery or other procedure planned that would interrupt their participation in the study
- Female participants who are able to become pregnant but are not willing to use the specific type of contraception required by the study, both during treatment and for 30 days after the last dose
- Female participants who are planning to become pregnant at any point during the study or within 30 days after their last dose
- Female participants who are able to become pregnant and have a positive pregnancy test at the start of this study (Week 0)
- Anyone with a known allergy or sensitivity to any of the products used in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: MD, Amgen
Phone: 866-572-6436
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with Adverse Events; Columbia-Suicide Severity rating Scale (C-SSRS); Tanner Staging; Change from Baseline in Body Weight; Change from Baseline in Height; Change from Baseline in Body Mass Index (BMI); Number of Participants with Clinically Significant Changes in Vital Signs; Number of Participants with Clinically Significant Changes in Laboratory Parameters
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.